Marubi(SH:603983) Sou Hu Cai Jing·2025-09-10 07:52Core Viewpoint - Marubi Biotechnology (SH603983) reported a significant increase in revenue and net profit for the first half of 2025, indicating strong business performance and growth potential in the skincare industry [1][2]. Financial Performance - The company achieved an operating income of 1.769 billion yuan, a year-on-year increase of 30.83% [2]. - The net profit attributable to shareholders was 186 million yuan, up 5.21% compared to the previous year [2]. - The net profit after deducting non-recurring gains and losses was 177 million yuan, reflecting a 6.64% increase year-on-year [1][2]. - Total profit for the period was 241 million yuan, representing a 7.17% increase from the same period last year [2]. - The net cash flow from operating activities was 116 million yuan, showing a substantial increase of 97.41% [2]. Cost Structure - Sales expenses reached 1 billion yuan, a year-on-year increase of 39.31%, primarily due to rising online traffic costs and ongoing investments in brand building and scientific communication [2]. - Management expenses were 50.5 million yuan, up 8.61% year-on-year [2]. - Research and development expenses totaled 40.7 million yuan, reflecting a 13.53% increase, indicating continued investment in innovation [2]. Executive Compensation - In 2024, the CFO Wang Kaihui and CMO Zeng Lingchun received salaries of 2.409 million yuan and 2.142 million yuan, respectively, both higher than the CEO Sun Huaqing's salary of 2.113 million yuan [3].